Business Of Biotech
About
Available on
Community
196 episodes
Weve really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimers Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karens thoughtful perspective on the sometimes tumultuous Alzheimers therapeutics space is valuable to any drug developer working in the cognitive medicines arena. In this episode of the Business of Biotech podcast, we follow Karens journey from institutional investment banking to the incredibly gratifying work she does now, helping to fund the novel biopharma companies that are working in earnest to solve an emotionally burdensome and expensive problem. Karen shares ADDFs strategy and offers plenty of insight into the value proposition that venture philathropy offers the biotech community. Tune in! Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneerings Generate Biomedicines, which bills itself at the "intersection of machine learning, biological engineering, and medicine." To get a grip on the "generative biology" work its doing and the AI/ML impact it anticipates in the discovery and development of therapeutics, as well as clinical trials, we sat down with veteran biotech builder Mike Nally, CEO at Generate and CEO-Partner at Flagship Pioneering. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into intensive care management roles. It wasnt until he left the hospital and entered biopharma that he found his footing, cutting his teeth in business development at places like Merck, Pfizer, Quark Pharma, and Teva. He even headed growth strategy at Lonza for a while. Now, hes Chief Business Officer and General Partner at CinRx Pharma, where a deep pipeline of early- to late-stage candidates keeps him on his dealmaking toes. Within minutes of our conversation, Dr. Sameuls introspective reflections on biotech dealmaking and negotiations planted this episode firmly on the Business of Biotech podcast highlight reel. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Rob Williamsons mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson isnt passive about honing his vision for progressive therapeutic dealmaking. Hes an active leader, and for this episode of the Business of Biotech, he took a breather from a hectic agenda at the J.P. Morgan Healthcare Conference to share some introspection on the work hes done, the work hes doing at Triumvira with T-cell therapeutics in oncology, the big opportunities in cancer therapeutics, and whats coming next. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
In biotech, when "one of these things doesnt look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it. Despite an approach to developing antibodies and other biologics that looks decidedly different--theyre developed from spirulina cell lines and, in some cases, designed for oral administration (gasp!)--Lumen Biosciences has won hard-fought funding from some nontraditional sources to continue its mission to democratize biologics. Finrow is Co-Founder & CEO at Lumen, and now a two-time guest of the Business of Biotech. Hes a Harvard J.D., but dont hold that against him. Hes one of the most approachable and transparent founders weve enjoyed the pleasure of hosting, and he didnt disappoint when we sat down for this talk in San Francisco. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely-related and necessary companion diagnostic arena. On today’s episode of the Business of Biotech, recorded in San Francisco, we sit down with Dr. Mark Hoppin, CEO of Ratio Therapeutics, a company that’s well-positioned in the space with a fresh Series B and the foundation of a tunable radiotherapeutic that Dr. Hoppin says addresses the delivery, safety and efficacy challenges long associated with radiopharmaceuticals in the treatment of solid cancers. We also discuss how this mathemetician-turned biotech CEO has navigated the leadership of boards, employees, and investors on his journey. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic. On this episode of the Business of Biotech, Dr. Pfefer takes us under the hood of Sail Biomedicines and its mission to marry evolution and AI to develop programmable medicines based on eRNA. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed. Its CEO, Dr. Mark Kotter doesn’t pull any punches when addressing the complexity involved in building out the company’s capabilities. At the discovery stage alone, bit.bio has hired – and integrated – stem cell biologists, synthetic biologists, genetic engineering experts, cellular biologists, sequencing experts, data scientists, bioinformatics pros, and machine learning experts. On this episode of the Business of Biotech, recorded in San Francisco during JPM Week, we catch up with Dr. Kotter on the work bit.bio is doing, how it’s doing it, and how he and his leadership team are recruiting and retaining a new breed of biotech talent to sustain the effort. Let’s give it a listen. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. Having acknowledged that, no first iteration of a new technology is ever the best iteration of that technology. On this weeks episode of the Business of Biotech, we welcome Carsten Rudolph, Ph.D., co-founder and CEO of a company that recognizes this room for improvement. Ethris is developing mRNA-based candidates for the treatment of respiratory viral infections and rare pulmonary diseases, in addition to mucosal, multivalent, and mutation-agnostic prophylactic vaccines. Dr. Rudolph explains the concept, the business case, and how hes navigating Ethris toward a better treatment and vaccine paradigm in the wake of the pandemic. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech builders. The results of that trip will feed the next several weeks of Business of Biotech podcast programming, and were kicking things off with everyones favorite life sciences CFO, Allan Shaw. On this episode, Allan shares whats driving the cautious optimism for biotechs return, pointing to factors like Decembers flurry of M&A activity, interest rate reductions, and easing inflation as just cause for the bullish sentiment that was palpable at the conference. We also discuss what could shift the tailwinds, namely the election year wildcard, and why biotech could benefit from a metered comeback. Come for the facts, stay for the Shawisms! Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies. The company’s a bit larger than those we typically cover on the Business of Biotech, and that’s okay! Sometimes, the smartest approach to creating your own masterpiece is to study the masters On this episode of the podcast, we sit down with Incyte’s Group Vice President and head of its Inflammation and AutoImmunity Group, Jim Lee, M.D., Ph.D. for a dissection of the company’s approach to the comprehensive and efficient R&D that leads to repeated clinical and commercial success. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics. In addition to how he’s built late-clinical stage Intellia, Dr. Leonard shares the foundational elements of a biotech community, particularly around rapidly-advancing technologies such as CRISPR, and what biotech ecosystems offer emerging biotechs in terms of resources, intellectual property, and support. Turns out that despite his proximity, Boston isn’t the prerequisite it used to be. This is an instructive conversation with an industry vet who’s happy to share the wealth of his knowledge. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Relatively new CEO Joseph Ferra has orchestrated some pretty significant change at Elevation Oncology in the two(ish) years since the Business of Biotech last hosted the company. In that short time, Ferra advance from CFO to CEO, a move that aligned very closely with the companys difficult decision to shelve the late phase 2 anti-HER3 monoclonal antibody candidate it was founded on. Those big moves set the stage for Elevations new lead candidate, a phase 1 Claudin18.2 target in the oh-so-hot ADC (antibody drug conjugate) space. On this episode of the Business of Biotech, we go behind the scenes to learn why and how those daring moves were made, and how Elevation navigated the gauntlet of risk it assumed when it embraced disruption in a not-so-shiny biotech market. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
A new year marks a fresh start for biotech partnerships, and to kick off 2024, were highlighting a good one. Fina Biosolutions Dr. Andrew Lees recently signed on with Scorpius BioManufacturing to support his companys growth plan. On todays episode of the Business of Biotech, Lees sits down with Scorpius VP of commercial operations Steve Lavezoli for a frank conversation on the ups, downs, and expectations of a biotech + CDMO relationship. In addition to contracts and master service agreements, the pair walk us through the day-to-day execution of the partnership and responsibilities of those involved in it. If youre considering signing on with an outsourced manufacturing partner, or thinking about making a switch, you wont want to miss this episode. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Merry Christmas, Business of Biotechers! On this Christmas Day release, we’re taking a trip to the land down under to visit with Dr. Sam Costello, a former gastroenterologist-turned managing director and co-founder at Adelaide, Australia-based BiomeBank. We covered some ground on this one, most notably the unique path BiomeBank took to chalking up the first donor-derived microbiome therapeutic approval of its kind, anywhere in the world. In a segment of biotech that’s been particularly battered of late, that’s a big, big win. We also talked about what’s behind Australia’s foray onto the global biotech scene, the public/private partnerships supporting that growth, why U.S. biotechs, in particular, are flocking there to conduct clinical trials, and whether Foster’s is really Australian for beer. Don’t miss it! Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
On this weeks episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonums transition from its predecessor, Good Therapeutics, which was fueled by a high-profile asset sale to Roche. The asset, a PD-1-regulated IL-2 program, was a product of a platform that the new Bonum retains, and its sale to Roche was orchestrated by Dr. Patel. Youve seen the terms of the deal in the news, but on this episode, youll get the inside scoop on how the deal was done, how it set Bonum up for future paltform-driven succes, and how these two leaders retained its IP and its people through a fast, unique, and disruptive acquisition. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
During his leadership of the Presidents Emergency Plan for AIDS Relief during the George W. Bush administraion, Dr. Mark Dybul, M.D. shepherded programs credited with saving more than 25 million lives. For many years after that public service drew to a close, he continued the mission as executive director of The Global Fund to Fight AIDS, Tuberculosis and Malaria--working in lockstep with not only the worlds leading scientists, but the likes of Bono and Sir Elton John along the way. But, it wasnt all glamor and heroics. Dybul had to influence some decidedly conservative global political machines of the importance of addressing the AIDS epidemic, particularly, at the time, in Africa. He had to fight through federal and global beuracracies for every dime of funding earned. His leadership required resolve in the face of complexity and adversity. Nothing could have better prepared him for biotech leadership, which has dealt Dr. Dybul an unfair share of unique adversity thats, quite frankly, the stuff of a Dateline NBC episode. On this epsiode of the Business of Biotech podcast, Dybul, CEO at Renovaro Biosciences, gets introspective on leadership forged in the fires of public service and battle-tested in the private sector. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Combined Therapeutics President & CEO Dr. Romain Micol is operating his company in a very noisy space, where hundreds of new biotechs have popped up on the coattails of a COVID-driven renewal of interest in mRNA vaccines. Micol recognizes that noise and the competition it brings for capital and mindshare. Hes not only aware of it — he welcomes it. On this quick episode of the Business of Biotech podcast, Micol shares the unique approach Combined Tx is taking to distinguishing itself in the mRNA infectious disease and cancer vaccine space, from the delivery, safety, efficay, and business perspectives. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
When it comes to landing and executing strategic partnerships, Regeneron https://www.regeneron.com/ puts on a clinic. Partnerships, acquisitions, licensing agreements, and other deals large and small with Intellia, Decibel Therapeutics, BARDA, Alnylam, and Sonoma Therapeutics are just a sampling of those making news this year alone. The man behind much of that dealmaking is none other than Nouhad Husseini, SVP and Head of Business Development and Corporate Strategy at Regeneron. He’s a guy who’s deftly married the art and science of biopharma dealmaking, and on this episode of the Business of Biotech podcast, we’re getting introspective with this legend in the making, who our friend Allan Shaw says “turns the deals he touches into gold.” Strategic dealmaking is central to the biotech business, and today’s episode offers a master class. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
From his vantage point as an independent biotech journalist, Luke Timmerman has been watching the expansions and retractions of the industry for a couple of decades now. His unique perspective is hard to equal, and that perspective is, despite tough markets and tepid public sentiment, decidedly bullish. Lukes optimism is fed by sound logic gained from a career spent in observation mode, watching the development of purpose-built tools matched to address the fragility of human biology. Lukes tireless advocacy for the industry also stretches well beyond his professional coverage and punditry. Through his Timmerman Traverse initiative, hes figured out a way to weave his personal and professional passions into a tapestery that serves some of the philanthropic initiatives our industry cares about most. On this episode of the Business of Biotech, well get to know Luke personally, well learn about his philanthropic work, and well give you a healthy dose of optimism as we look ahead to the next decade in biotech. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Earlier this year, Shawn Davis, Ph.D. left a pretty comfortable position at AstraZeneca (and Amgen before that, and Milliken, and others, before that) to lead Liberate Bio. He brought along another industry notable in Merck/Intellia alumnus Walter Strapps, Ph.D., who serves as CSO at Liberate. Whyd they do it? Because RNA delivery is such a crucial step toward revolutionary genetic medicine, but its tough science. They think they can change that. On this episode of the Business of Biotech, Drs. Davis and Strapps share how theyre applying automation and machine learning technologies to minimize the challenges associated with targeted delivery of genetic medicine and overcome the limitations of AAV. During our conversation, they both leaned hard into how their previous experiences have shaped the work theyre doing, and the wide-open business opportunities Liberate Bio is creating. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Shortly after Thalidomide became a household word—albeit a very, bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did. Today, Thalidomide is the foundation of cancer drugs worth billions of dollars. Gorlin doesnt own it anymore, but the story of how he got it is just one of the experiences that contributed to the codification of his "golden rules." Following those rules has paid off. SIx of the companies hes founded acieved valuations, or sold, for more than $1 billion each. This week, the Business of Biotech sits down with the legendary biotech investor Steve Gorlin, now CEO of CoRegen, for a conversation on his golden rules for picking winners. Gear up for an action-packed, LIVE, and INTERACTIVE Business of Biotech as we delve into the nitty-gritty of IP and legal considerations crucial for budding biotech entities. Get your queries resolved straight from a seasoned professional, minus the lawyers fees! YOU HAVE TO REGISTER FOR THIS ONE (no cost), so head to tinyurl.com/boblive23, or secure your spot for https://event.on24.com/wcc/r/4376909/58114AA2A39F50879AE1B6F0CD1F5B11?partnerref=Pod171Join us on Monday, November 13th, at 11 am Eastern. You dont want to miss this! Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Register for https://event.on24.com/wcc/r/4376909/58114AA2A39F50879AE1B6F0CD1F5B11?partnerref=Pod171Get ready to unravel the legal enigmas of the biotech world with me and Keir LoIacono, Esq. The CEO of Blue Sphere Bio, Keir is no stranger to high-stakes decision-making and legal conundrums in the biotech industry. Having served as the general counsel and VP of Corporate Development for Oncosec, lead in-house counsel and senior director for Advaxis, and intellectual property attorney at the leading biotech law firm Lerner, David, Littenberg, Krumholz, and Mentlick, Keir is a powerhouse of knowledge ready to share his insights. Gear up for an action-packed, LIVE, and INTERACTIVE Business of Biotech as we delve into the nitty-gritty of IP and legal considerations crucial for budding biotech entities. Get your queries resolved straight from a seasoned professional, minus the lawyers fees! YOU HAVE TO REGISTER FOR THIS ONE (no cost), so head to tinyurl.com/boblive23, or secure your spot for https://event.on24.com/wcc/r/4376909/58114AA2A39F50879AE1B6F0CD1F5B11?partnerref=Pod171Join us on Monday, November 13th, at 11 am Eastern. You dont want to miss this! Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its contract develpment and manufacturing outsourcer (CDMO)? Jenny Holt, Chief Development Officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, Chief Commercial Officer at the CDMO Forge Biologics. Think they align? On this episode of the Business of Biotech, we dig into the trust, technical expertise, and project timeline considerations that required of a successful partnership. We also broach the risks associated with emerging CDMOs, the right balance among cost, quality, and time, what you should ask when evaluating outsourcing partners, and a whole lot more. ***REGISTER for the first-ever, interactive https://event.on24.com/wcc/r/4376909/58114AA2A39F50879AE1B6F0CD1F5B11?partnerref=Pod171 Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
On a road trip to Boston, the Business of Biotech caught up with podcast alum Dan Passeri, J.D., CEO at Cue Biopharma, and enjoyed a two-for-one with CSO & President Anish Suri, Ph.D. at Cues headquarters just feet below the Auerbach Center. Among other things, we discussed the duos complementary leadership approach as the company takes multiple candidates into the clinic, why Passeri leans into his biotech legal background almost every day hes at work, the successful navigation of outsourced manufacturing relationships, why Cues discretely targeted IL-2 approach eliminates the absurdity of early IL-2 failures, and a whole lot more. Speaking of Dans legal background, before you jump into todays episode, REGISTER for the first-ever, interactive https://event.on24.com/wcc/r/4376909/58114AA2A39F50879AE1B6F0CD1F5B11?partnerref=Pod171 Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/! Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Johanna Kaufmann, Ph.D.s path to EVP, Oncology at Codagenix is part serendipity and part circumstance, but its a much larger part hard work. On this weeks episode of the Business of Biotech, Dr. Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the personal professional and personal development regimens she subscribes to. We also catch up on the important work Codagenix is doing in the live vaccines and viral therapeutics arena. ***REGISTER for the first-ever, interactive https://event.on24.com/wcc/r/4376909/58114AA2A39F50879AE1B6F0CD1F5B11https://event.on24.com/wcc/r/4376909/58114AA2A39F50879AE1B6F0CD1F5B11 Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
On this episode of the Business of Biotech, Leonard Mazur, co-founder, CEO, and chairman of Citius Pharmaceuticals, shares his rollercoaster ride to success in biotech, the founding story of Citius Pharmaceuticals, his engagement with the Department of Defense, and the effort to revive an antibiotic used on the frontlines. Leonard takes us into the complexity of investor relationships, and his personal investment that influences his leadership style. He reveals his strategies for constructing a successful biotech pipeline, underscoring the importance of a unique mechanism of action and the hurdles of resurrecting a retired product. Get ready for an intimate look at Leonards decision-making process, and his insights into managing the financial aspects of a bio-pharma company. As we wrap up, Leonard offers an honest look at the evolution of the biotech industry, the financial challenges faced, and his advice on navigating these turbulent waters. He brings his experience with auction processes and drug hunting to light, preparing us for unexpected hiccups in the biotech world. Leonard also credits mentorship in shaping his approach to constructing a clinical pipeline. Join us for this inspiring exploration of resilience, determination, and success in the biotech industry. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Dont be offended by the title of todays Business of Biotech podcast. Dr. Quin Wills application of whats become known as "Wheatons Law" (look it up) is central to the ambitious goals his company, Ochre Bio, is pursuing: pioneering the value of computational biology in large mol discovery and development, putting an end to the global liver disease epidemic, and changing the costly, high-risk approach to clinical trials. On this weeks episode, Dr. Wills and I explore how those goals are being addressed despite the challenges they present, and how the companys three guiding principles, dont be a d*** being one of them, align the Ochre team with the mission at hand. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
This weeks guest on the Business of Biotech, EVQLVs Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say theyre doing it really arent, and the one who really are arent talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware? In our talks with the leaders of new and emerging biotechs over the past 12 to 18 months, weve seen a steep increase in the application of – or at the very least, interest in – machine learning, AI, and computational biology tools for drug discovery, development, and beyond. Even those who are using some "ultra-light" application of new computational technology are eager to talk about it, as it’s clearly become as en-vogue as tacking “bio” onto your moniker was a few years back – even among companies who aren’t actually developing biologics. On this episode, Satz offers his take on the reality of adoption and shares advice on the fundamentals of AI and ML in biotech. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
Orca Bios Dan Kirby has played a hand in prepping more than a few approved biologic therapeutic candidates for commercialization. Equally important, he knows firsthand what makes or breaks post-approval commercial efforts, having played virtually every role there is to play in drug sales and marketing. He "carried the bag" for GSK in his early days, directed oncology marketing efforts at Amgen, and led marketing and U.S. commercial efforts at Juno, then Celgene after it acquired the former. Kirby joined Orca Bio in timely fashion back in 2020, as today the company ushers its first cell therapy into phase 3 clinical trials, with strategically-dispersed follow-up candidates spanning all phases back to R&D. On this weeks episode of the Business of Biotech, we get a one-on-one commercialization preparation discussion with one of the best in the business, and the straight-talking veteran doesnt disappoint in the strategy and insight departments. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/ for more real, honest, transparent interactions with the leaders of emerging biotech. Its a once-per-month dose of insight and intel that ! Check it out at bioprocessonline.com/bob https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/!
